Summary & Overview
CPT 90393: Vaccine Immune Globulin for Smallpox Prophylaxis
CPT code 90393 identifies Vaccine Immune Globulin (VIg), a human plasma–derived antibody product collected from donors repeatedly vaccinated against smallpox. Nationally, this code is significant for public health preparedness and for clinicians managing exposures or high-risk patients requiring passive immunization against smallpox. Use of VIg is typically limited to specialized settings and events where smallpox exposure is suspected or for prophylaxis in defined clinical scenarios.
Key payers addressed in this overview include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication outlines payer coverage patterns, where available, and places the code in clinical and policy context relevant to national immunization and biodefense planning.
Readers will learn what CPT code 90393 represents, the clinical situations in which VIg is used, the typical sites of service for administration, and which major payers are commonly involved in coverage discussions. The summary also indicates where input data was unavailable. This information supports coding accuracy, billing workflows, and coordination between clinical teams and payers for the administration of passive immunotherapy against smallpox.
Billing Code Overview
CPT code 90393 represents Vaccine Immune Globulin (VIg), a preparation of human plasma-derived antibodies collected from donors who have received the smallpox vaccine more than once. This product is used to prevent or boost immunity to smallpox in patients at risk of exposure or with specific clinical indications for passive immunization.
Service Type: Passive immunotherapy / Immune globulin administration
Typical Site of Service: Hospital outpatient clinics, emergency departments, public health clinics, and specialized infusion centers
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult or pediatric individual who has been exposed to or is at high risk for variola (smallpox) infection, or a laboratory worker with potential occupational exposure to orthopoxviruses. The patient presents to a hospital infectious disease service, public health clinic, or occupational health clinic for administration of Vaccine Immune Globulin (VIg) to provide passive immunity or to boost immunity after vaccination complications. The clinical workflow includes: initial triage and exposure assessment; review of smallpox vaccination history and contraindications; informed consent and documentation; ordering of 90393 and preparation by pharmacy or designated immunization staff; screening for hypersensitivity to blood products; administration of VIg by intravenous or intramuscular route per protocol; observation for immediate adverse reactions (typically 30–60 minutes); documentation of lot number, manufacturer, dose, administration route, and site; and follow-up for delayed reactions and effectiveness assessment. Typical sites of service are hospital inpatient units, emergency departments, occupational health clinics, and public health vaccination centers.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier | Use when no specific modifier applies and service is billed without adjustment. |
52 | Reduced services | Use when less than full dose or reduced service is provided relative to standard VIg administration.